Matthew is the head of Bristows’ Commercial IP group and advises on transactions involving the development, exploitation and transfer of intellectual property rights. His scientific background is of particular assistance when negotiating and advising on transactions involving new technologies. He has advised on a number of successful global licensing programmes for the exploitation of new technologies and has also advised in relation to international patent pooling arrangements.
He works across many sectors but has particular experience in the pharmaceuticals, biotechnology, medtech, electronics, software, telecoms, petrochemical, cleantech and other industrial sectors. Matthew’s experience in negotiating commercial contracts for pharmaceutical, biotechnology and medtech clients includes technology licensing agreements, R&D collaboration agreements, drug development and licensing agreements, clinical trial agreements and option agreements for licences. He also advises pharmaceutical and biotechnology clients on the commercial and intellectual property law aspects of manufacturing, distribution, co-promotion and marketing agreements.
The negotiation of agreements to resolve disputes involving intellectual property rights forms a significant part of Matthew’s practice. This has included global settlements to end litigation across multiple jurisdictions involving complex intellectual property, licensing and financial arrangements.
He advises on the intellectual property aspects of setting up joint ventures and other collaborations including in relation to the ownership and licensing of intellectual property and improvements. Matthew has particular experience advising on intellectual property issues relating to technical standards including FRAND terms for licensing standard essential patents.
He has given presentations on the impact of the new European Unitary Patent and the Unified Patent Court on agreements under which inventions/patents are created and licensed and how such agreements should be drafted to deal with the new European Unitary Patent.
Matthew was involved in setting up the IP Transactions Course at the UCL Faculty of Laws, University College London and lectures on the course.
- BSc Physics, Imperial College, London
- Diploma in Intellectual Property Law and Practice, University of Bristol
- Qualified 1991
- Partner 1998
What others say
"Bristow’s litigation prowess is matched by its redoubtable transactional offering. Head of commercial IP Matthew Warren has been pivotal in the establishment of a partnership between Illumina and Genomics England, and on the latter’s 100,000 Genomes Project; “he is considered and patient when dealing with multiple stakeholders, and displays an impressive ability to think creatively”."IAM Patent 1000 2017
"Matthew Warren...praised for [his] ‘commercial awareness and technical ability’."Legal 500 2016
"Practice head Matthew Warren is particularly experienced in the pharmaceutical and biotechnology sectors."Legal 500 2016
"Matthew Warren is ‘a very strong practitioner who is highly perceptive and knowledgeable’. He is at his very best advising biotechnology clients on R&D collaboration agreements and patent commercialisation’.”IAM Patent 1000 2016
"The 'highly intelligent' Matthew Warren directed the team’s efforts, showcasing his ability to 'handle complex agreements with real finesse'.”IAM Patent 1000 2015
Best Lawyers™ in the United Kingdom for Intellectual Property Law
Legal 500 2020/2019/2018
Legal 500 2020/2019/2018
Patent Strategy & Counseling
MIP, IP Stars 2019/2018
Transactions: Highly recommended
IAM Patent 1000 2018